key: cord-0912165-sgwenxdt
authors: Austgen, Gabriela; Meyers, Matthew; Gordon, Mollie; Livingston, Robin
title: “The Use of Electroconvulsive Therapy in Neuropsychiatric Complications of COVID-19: A systematic literature review and case report”
date: 2021-08-04
journal: J Acad Consult Liaison Psychiatry
DOI: 10.1016/j.jaclp.2021.07.010
sha: c5fc890d36b3103c2b94a16cc6f5438f0173fee4
doc_id: 912165
cord_uid: sgwenxdt

Objective This study reports on the use of electroconvulsive therapy (ECT) in neuropsychiatric symptoms (NPS) associated with COVID-19. Methods A review of the literature pertaining to the use of ECT in COVID-19 patients with NPS was performed through PubMed, PsycINFO, and MEDLINE. Search terms included “Electroconvulsive Therapy” and “ECT,” combined with “COVID-19” and “SARS-COV-2.” Additionally, we present a case in which ECT was used to achieve complete remission in a patient who developed new onset, treatment-resistant depression, psychosis, and catatonia, associated with COVID-19. Results 67 articles were reviewed with 3 selected for inclusion. These articles detailed 3 case reports of patients with new onset NPS (mania, psychosis and suicidality, and catatonia) that developed in the context of active COVID-19 and were treated successfully with ECT. Conclusions There is a significant prevalence of new onset NPS, some severe and persistent, in COVID-19 patients. ECT, a broad-spectrum treatment that has been found to be effective in various NPS (independent of etiology), is shown in our case report and others, to be safe and effective for NPS associated with COVID-19. Though we identified only 3 other cases in the literature, we believe that the probable anti-inflammatory mechanism of ECT, its safety and tolerability, and the faster time to symptom remission support the need for more research and increased clinician awareness about this life-saving procedure.

INTRODUCTION COVID-19, the illness caused by SARS-CoV-2 infection, has been increasingly recognized to be associated with neuropsychiatric complications such as delirium, depression, psychosis, and catatonia 1,2 . While the underlying pathophysiology of neuropsychiatric symptoms (NPS) in COVID- 19 is not yet well understood, these complications are thought to be caused by direct CNS invasion or indirect neuroinflammation which develops during the acute infectious period 1 . Reports on NPS in COVID-19 patients demonstrate a significant prevalence, with some persisting long after acute illness resolution [3] [4] [5] . In one study of 40,496 patients diagnosed with COVID- 19, 22 .5% were found to have NPS 3 . In a surveillance study of 153 COVID-19 patients in the UK, almost 60% of patients that presented with AMS were found to have NPS. Alarmingly, over 90% of the neuropsychiatric presentations were classified as new diagnoses, which included psychosis, affective disorders and "dementia like" syndromes 4 . The high prevalence of these complications, sometimes extending far beyond diagnosis and hospital stay 5 , underscores the need for safe and effective treatment options.

ECT has been used since the 1930s as a treatment for severe psychiatric conditions, particularly those resistant to pharmacotherapy 6 . ECT has been found effective for depression, mania, psychosis, agitation in delirium, and catatonia 7, 8 . ECT has also been used to treat psychiatric symptoms that develop as a result of autoimmune-driven inflammatory processes 9, 10 . The nonspecific neuropsychiatric syndrome of catatonia can be caused by both medical and psychiatric conditions, including infection, and is responsive to ECT 11, 12 . COVID-19 may result in psychiatric sequelae, acute and chronic, which may be managed by ECT.

An overwhelmingly safe and well-tolerated procedure, ECT has no absolute contraindications 8, 13 . ECT is highly effective compared to medications and may provide the benefit of faster time to remission 6 . Because of the increasing evidence of psychiatric manifestations of COVID-19, some of which can become severe and life-threatening, we believe that more clinicians need to be made aware of this important treatment option. Isolation requirements, limitation on procedures, and possibility of aerosolization specific to ECT, have impaired access to this effective and necessary procedure during the pandemic 14 . Despite these challenges, NPS of infectious diseases highlights the need for ECT to remain a non-elective procedure during global pandemics. We agree with the many articles already published that have voiced concern over this major problem in ECT access [14] [15] [16] . The following case report and review of the literature emphasizes the important potential role of ECT in the treatment of COVID-19 NPS. 

A 52-year-old woman without prior psychiatric history was admitted to our hospital in March 2021 for depression and psychosis, which developed during mild COVID-19 illness. The patient had well-controlled type II diabetes, mild hypertension, and post-viral reactive airway disease periodically requiring oral steroids. She was otherwise healthy and working full-time before symptom onset.

After testing positive for COVID-19 by PCR in early January 2021, the patient's primary care provider (PCP) prescribed azithromycin and prednisone 50 mg for mild upper respiratory symptoms. She developed insomnia and anxiety; symptoms progressed despite selfdiscontinuation of prednisone after 2 doses. In early February, she was hospitalized by her PCP for worsening depression and paranoia.

Brain MRI with and without contrast, EEG, serum rheumatologic panel (Footnote 1), CSF (Footnote 2), and encephalitis panel (Footnote 3), were negative. Notably, CSF IgG was mildly elevated (4.15), as were ferritin (238 ng/mL), CRP (1.35 mg/dL), ESR (34 mm/hr), and IL-6 (17 pg/mL).

Given suspicion for a neuroinflammatory etiology of the symptoms, the patient was treated with 5 days IV methylprednisolone 1000 mg, with minimal, temporary improvement. Psychopharmacological trials of short duration were attempted without significant change (escitalopram to 10 mg for 3 days, sertraline to 100 mg for 5 days, risperidone to 3 mg for 8 days, aripiprazole to 15 mg for 10 days, olanzapine to 15 mg for 10 days). She was discharged to a neurorehabilitation center and presented to our hospital within 48 hours for evaluation of suicidal thoughts.

The patient presented with depressed mood, psychomotor slowing, paranoia, and nihilistic delusions. She was started on olanzapine 10 mg and sertraline 100 mg. Given symptom severity and minimal improvement with psychopharmacology, ECT consult was placed. Though initially hesitant, she demonstrated capacity for consent and received her first treatment of bitemporal ECT on hospital day (HD) 19. The first 3 treatments were not ideally spaced (QOD) due to the patient's delusions interfering with treatment.

ECT infrequency and disease progression likely contributed to worsening withdrawal and motor symptoms concerning for catatonia. Olanzapine was discontinued, but the patient's oral intake continued to decline, and by HD 26 (after ECT #3), she developed full catatonia. 4 . Somatics Thymatron System IV, pulse width 0.5 msec, current 0.91 amps, stimulus duration 8 sec, frequency 70 Hz, charge 508.6 mC On HD 27, the patient was immobile, negativistic and mute, with a Bush Francis Catatonia Rating Scale (BFCRS) score of 18. She was transferred to a medical unit for fluids and IV lorazepam. By HD 30, she was able to consent to restart ECT, and she completed treatments 4-9 on a MWF schedule. Treatments were confounded by concurrent use of lorazepam, 8 mg total daily. Despite use of flumazenil (up to 1mg), seizures were of short duration, and she was rapidly uptitrated to 100% energy (Footnote 4).

As the index course progressed, the patient's mental status improved substantially. Her BFCRS and MADRS scores dropped to 0 (Figure 1 ). Post ECT, lorazepam was tapered completely, without recurrence of catatonia. She showed a marked improvement in affect, interpersonal engagement, and self-care. She was discharged to family on HD 47, and continued in her recovered state at 1-month psychiatric follow-up.

We conducted a review of available literature on the use of ECT in patients with psychiatric complications of COVID-19. PubMed, MEDLINE, and PsycINFO databases were searched independently by 2 of the authors (G.A. and R.L.). The following terms were used: "Electroconvulsive Therapy" and "ECT," combined with "COVID-19" and "SARS-COV-2." These searches were performed in May 2021 and included literature published from 2020 onward. A total of 67 results were returned, after removing duplicates. The full texts of English language articles meeting inclusion criteria were reviewed. Details extracted from each case report included the patient's age, psychiatric diagnoses, onset of psychiatric illness in relation to COVID-19 infection, details of ECT treatment, and outcome of treatment.

Inclusion/Exclusion Criteria Included texts described administration of ECT to patients with psychiatric illness that developed in the context of COVID-19 infection. Only articles available in English language were included. Texts excluded did not pertain to the use of ECT in patients with psychiatric complications of COVID-19 specifically. If the patient's psychiatric indication for ECT predated the COVID-19 infection, the article was excluded, even if there was a decompensation related to COVID-19. (Fig. 2) 

After excluding 64 articles that did not meet our criteria, 3 articles were included in our review [17] [18] [19] . Through this review we identified 3 patients that developed psychiatric problems during COVID-19 infection and who were treated with ECT. Extracted data are summarized in Table 1 . Kashaninasab et al. describe a 25-year-old male who experienced a "first episode" of severe mania with psychotic features in the context of COVID-19 illness. Acute symptoms were not responsive to antipsychotics, so ECT was started on HD 3. After 6 treatments, he was discharged on sodium valproate 1500 mg daily with controlled psychotic and mood symptoms 17 .

Chacko et al. report on a 52-year-old male with obstructive sleep apnea and no prior psychiatric history who developed psychosis and mutism after a COVID-19 exposure. Symptoms were initially relieved with lorazepam, and the patient was clinically diagnosed with COVID-19 and discharged on antibiotics. He was re-admitted to the hospital for ongoing psychosis and suicidality. He remained suicidal despite pharmacotherapy; therefore, ECT was initiated. He was discharged on oral medications and in improved condition after 6 treatments 18 .

Deocleciano de Araujo et al. report on a 50-year-old male with IDD and well controlled epilepsy who presented with catatonia and COVID-19, diagnosed by PCR. Though initially in critical condition (requiring ICU stay) and progression to malignant catatonia despite benzodiazepines, the patient returned to baseline after 10 treatments of ECT 19 .

Post-infectious NPS, including psychosis, catatonia, and affective disorders, have been documented as early as the 19 th century 1,20,21 . The association is especially strong for respiratory viruses such as influenza 1 ; in 1926, Karl Menninger, writing about post-influenza psychoses in a group of 200 patients, described influenza as having "almost unequal neurotoxicity" 22 . The early 1900s encephalitis lethargic pandemic, temporally associated with the Spanish Flu but now thought to have been caused by another pathogen, caused catatonia and post-encephalitic parkinsonism 23 . Catatonia has been reported to be caused by numerous other viral infections 24 . Exposure to certain viruses, including influenza and coronaviruses, have been found to be associated with mood disorders 21, 25 . Data from various studies have provided evidence of the potential of coronaviruses, a common cause of respiratory infections, to have NPS 26 . Reports of SARS-CoV-1 27,28 , MERS-CoV 28 , and now SARS-CoV-2 have identified specific NPS, including psychotic, mood, and cognitive symptoms that have been diagnosed during these illnesses 4, 27, 28 .

There are several potential mechanisms by which Sars-CoV-2 could cause NPS. The first mechanism is by direct invasion of CNS. Coronaviruses are "neurotropic:" they are capable of infecting neurons 26, 29 . This can be accomplished through nasal mucosal invasion through the cribriform plate, or through other peripheral nerves 30 . Coronaviruses could also invade CNS hematogenously 29 .

The second mechanism by which SARS-CoV-2 could cause NPS is by neuroinflammation secondary to a general immune response 1,27 . Troyer et al. further group this indirect neuroinflammation into cytokine network dysregulation, peripheral immune cell transmigration, and post-infectious autoimmunity. Case reports of catatonia in COVID-19 describe rise in proinflammatory markers, hypothesized to alter basal ganglia function, that accompanies onset of catatonia 2,31 . Similarly, Ferrando et al. demonstrated the same pattern of rise in inflammatory markers in 3 patients that developed psychosis associated with asymptomatic COVID-19 27 . Depression has also been found to be associated with increased inflammatory markers, and may be a common psychiatric complication of infection 24 .

Our patient's history and exam suggest that she developed COVID-19 associated NPS due to neuroinflammation during acute infection. First, despite nasal swab SARS-CoV-2 PCR positivity persisting for months, there was no SARS-CoV-2 RNA found in her CSF. Additionally, the patient's labs were mostly unremarkable, except for an increase in serum inflammatory markers: ferritin, ESR, CRP, IL-6: a pattern of findings described in other case reports, including those describing catatonia 2,31 and psychosis 27 secondary to COVID-19. The patient's CSF IgG was also above normal, suggesting a disruption in the blood brain barrier. Notably, elevated inflammatory markers were also described in 1 of the 3 case reports identified by our literature review 18 , and elevated WBC and CSF protein in another 19 .

The mechanism of action of ECT is not well understood. Proposed mechanisms include changes in regional blood flow and metabolism, increased BDNF, angiogenesis and neurogenesis, normalization of cortisol levels, enhancement of dopamine transmission and regulation of overactive glutamate transmission 32 . Importantly, multiple sessions of ECT lead to a decline in levels of inflammatory mediators 32 . ECT has been used effectively in treatment of psychiatric complications of autoimmune encephalitis 9 and in other conditions, such as major depression and Parkinson's 33 , in which there has been increasing interest in association with inflammation 24 . If ECT partially or fully reverses the chemical, structural, and functional changes associated with infection-induced neuroinflammatory state, we argue that ECT should be considered as a treatment option to improve outcomes and prognosis in post-COVID-19 neuropsychiatric disorders.

Limitations were found in our study. The methods of COVID-19 diagnosis used in the identified case reports are inconsistent. One did not clearly specify the method of diagnosis 17 . In another, the patient was diagnosed clinically, and this was later confirmed with a positive IgG 18 .

A confounding factor in our case is the patient's use of prednisone 50 mg x 2 doses, which was temporally associated with onset of her symptoms. Though we initially considered steroidinduced mood and psychotic disorder, several important points in the history contradicted this: the patient's prior use of prednisone without adverse effects, the low total dose of prednisone, and the persistence and worsening of symptoms despite steroid discontinuation. There is at least one large case-control study of SARS-CoV-1 patients to support this: though nearly all cases of acute psychosis were attributed to steroid use, those patients were treated with much larger daily and cumulative doses of corticosteroid. Additionally, the authors concluded that individual J o u r n a l P r e -p r o o f factors determining susceptibility to psychosis were also relevant 34 . We speculate that at most, our patient's steroid use may have potentiated symptoms in an already susceptible individual. CONCLUSION This is the 4 th case of COVID-19-associated severe psychiatric symptoms responsive to ECT. Our case is unique in that it describes acute and chronic psychiatric sequelae of COVID-19, all of which responded to ECT. The cases identified in our literature review, heterogeneous in patient characteristics and their psychiatric diagnoses (catatonia, psychotic, and mood disorders), support that ECT is effective in a "broad-spectrum" of psychiatric problems, and specifically, that it is safe, well-tolerated, and effective in NPS associated with COVID-19. As our case and the others have demonstrated, COVID-19-associated NPS can be severely disabling and even life-threatening: this suggests a role for early and aggressive use of ECT for psychiatric sequelae of COVID-19. 

Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms

COVID-19 and Catatonia: A Case Series and Systematic Review of Existing Literature

Spectrum of neuropsychiatric manifestations in COVID-19

Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study

Frequent neurocognitive deficits after recovery from mild COVID-19

Clinical Manual of Electroconvulsive Therapy

Clinical Manual of Electroconvulsive Therapy

Electroconvulsive Therapy in Geriatric Psychiatry: A Selective Review

Electroconvulsive therapy and/or plasmapheresis in autoimmune encephalitis?

A case of neuropsychiatric lupus with severe malignant catatonia that improved with daily electroconvulsive therapy

The Probability That Catatonia in the Hospital has a Medical Cause and the Relative Proportions of Its Causes: A Systematic Review

Catatonia in the medically ill: Etiology, diagnosis, and treatment. The Academy of Consultation-Liaison Psychiatry Evidence-Based Medicine Subcommittee Monograph

Adverse Effects

Electroconvulsive Therapy During COVID-19-Times: Our Patients Cannot Wait

The Other Victims of COVID-19: The Value of Electroconvulsive Therapy

Electroconvulsive Therapy during COVID-19: An Essential Medical Procedure-Maintaining Service Viability and Accessibility

Comorbidity of Coronavirus disease (COVID-19) and the first episode of bipolar disorder and its treatment challenges: A case report

COVID-19-Induced Psychosis and Suicidal Behavior: Case Report

Life-Threatening Catatonia Associated With Coronavirus Disease

COVID-19 and psychosis risk: Real or delusional concern?

Association of seropositivity for influenza and coronaviruses with history of mood disorders and suicide attempts

The first psychiatric pandemic: Encephalitis lethargica

Catatonia and the immune system: a review. The Lancet Psychiatry

Association between virus exposure and depression in US adults

Coronavirus immunoreactivity in individuals with a recent onset of psychotic symptoms

COVID-19 Psychosis: A Potential New Neuropsychiatric Condition Triggered by Novel Coronavirus Infection and the Inflammatory Response?

Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic

Human coronaviruses and other respiratory viruses: Underestimated opportunistic pathogens of the central nervous system? Viruses

Neurological manifestations of COVID-19 and other coronavirus infections: A systematic review

Catatonia in a hospitalized patient with COVID-19 and proposed immune-mediated mechanism

How electroconvulsive therapy works?: Understanding the neurobiological mechanisms

The Use of Electroconvulsive Therapy in Eating Disorders: A Systematic Literature Review and Case Report

Factors associated with psychosis among patients with severe acute respiratory syndrome: A case-control study

☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:J o u r n a l P r e -p r o o f